Sökning: "R-CHOP"

Hittade 4 avhandlingar innehållade ordet R-CHOP.

1. 1. Clinical and Molecular Studies of Diffuse Large B-cell Lymphoma

   Författare :Amal Abu Sabaa; Gunilla Enblad; Peter de Nully Brown; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; DLBCL; R-CHOP; EFS24; PEA; Biomarker; ELISA; TCL1A.;

   Sammanfattning : The general aim of this thesis was to study the prognostic clinical and biological markers of Diffuse Large B-cell Lymphoma (DLBCL).Paper I: Utilizing population-based data for patients with DLBCL in Sweden, the study aimed to establish whether event free survival at 24 months (EFS24) was a reproducible milestone. LÄS MER

3. 2. Prognostic signficance of tumor cell markers in diffuse large B-cell lymphoma with special emphasis on lymphoma localization

   Författare :Maysaa Abdulla; Rose-Marie Amini; Gunilla Enblad; Wolfram Klapper; Uppsala universitet; []
   Nyckelord :;

   Sammanfattning : Diffuse large B-cell lymphoma (DLBCL) is the most common type of high-grade B-cell lymphoma with different clinical, morphological, immunophenotypical, and molecular features. DLBCL is curable in 60-70% of patients when treated with standard immunochemotherapy R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). LÄS MER

4. 3. Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms

   Författare :Tove Wästerlid; Tumörmikromiljö; []
   Nyckelord :Burkitt Lymphoma; Chemotherapy; SOX11; Diffuse large B-cell lymphoma; Prognostic factors; Rituximab;

   Sammanfattning : Burkitt lymphoma (BL) is a rare, aggressive disorder constituting 1% of all non-Hodgkin lymphoma. Diffuse large B-cell lymphoma (DLBCL) is more common, accounting for 30% of malignant lymphoma. Standard treatment for adult BL and for certain subgroups of patients with DLBCL remains to be defined due to paucity of randomised trials performed. LÄS MER

5. 4. Clinical and tumour biology studies of Diffuse Large B-cell Lymphoma : with emphasis on comorbidity, toxicity and outcome

   Författare :Charlott Mörth; Gunilla Enblad; Kristina Drott; Uppsala universitet; []
   Nyckelord :DLBCL; autoimmune disease; cardiac toxicity; neurotoxicity; EFS; OS; Medicinsk vetenskap; Medical Science;

   Sammanfattning : Diffuse large B-cell lymphoma (DLBCL) is curable in around 70% when treated with standard immunochemotherapy R- CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). Treatment related toxicity affecting survivors is a clinical problem as well as comorbidities influencing the possibility to give adequate treatment. LÄS MER